At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 250 enrolled
Drug / intervention
Standard of Care (SOC) and Colchicine+Rosuvastatindrug
Likely dose
Standard of Care (SOC) and Colchicine+Rosuvastatin 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial
In Brief
A Phase 3 clinical trial evaluating Standard of Care (SOC) and Colchicine+Rosuvastatin for SARS-CoV-2. Completed, enrolled 250 participants across 4 sites.
Detailed Summary
This is a pragmatic randomized open-label study of the safety and efficacy of the combination of colchicine and Rosuvastatin in addition to standard of care (SOC) compared to SOC alone in hospitalized patients with SARS-CoV-2
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJul 2020
Enrollment StartOct 2020
Primary CompletionMar 2022
TodayJul 2026
First PostedJul 15, 2020
Enrollment StartOct 30, 2020
Primary CompletionMar 30, 2022
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.0 years ago
Interventions
Standard of Care (SOC) and Colchicine+Rosuvastatindrug
Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization